A Look At Hercules Capital (HTGC) Valuation After The Expanded Savara Loan Agreement

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.

Why the Savara loan amendment matters for Hercules Capital

Hercules Capital (HTGC) drew investor attention after Savara Inc. amended its loan and security agreement, creating access to up to an additional $75 million of capital tied to FDA approval of MOLBREEVI.

For Hercules, this updated facility shapes its exposure to Savara’s potential commercialization plans, since the added capacity, alongside Savara’s $75 million royalty financing, points to a larger pool of non dilutive funding linked to the therapy’s progress.

See our latest analysis for Hercules Capital.

The Hercules Capital share price has been relatively steady around US$18.70 in the short term, with a 90 day share price return of 5.35%. The 3 year total shareholder return of 82.37% and 5 year total shareholder return of 110.50% point to a very strong longer term record. As a result, recent news like the Savara amendment may be viewed more as fine tuning expectations around growth and risk than a major shift in sentiment.

If this kind of credit story interests you, it might be worth broadening your search and checking out fast growing stocks with high insider ownership as a way to spot other potential opportunities.

With Hercules Capital trading around US$18.70 and sitting at roughly a 12% discount to analyst price targets and a similar implied discount to intrinsic value, the key question is whether this represents genuine value or whether the market already reflects its future growth.

Most Popular Narrative: 11.9% Undervalued

Compared with the last close at $18.70, the most followed narrative points to a fair value of about $21.22, putting Hercules Capital on the undervalued side of the ledger based on those assumptions.

• Sustained expansion in the technology and life sciences sectors continues to drive record growth in new loan originations and fundings for Hercules, supporting robust revenue and net investment income growth into 2026.
• The increasing trend among startups and high-growth enterprises to seek non-bank, specialty lending amid regulatory constraints on traditional banks expands Hercules' pipeline, fueling portfolio growth and supporting higher long-term earnings.

Read the complete narrative.

Want to see what kind of revenue runway and margin profile has to hold up to justify that higher fair value and earnings path? The narrative leans on a specific growth pace, higher margins, and a steady profit multiple that matches today. Curious how those three pieces are stitched together across the next few years? The full story lays out the exact mix.

Story Continues

Result: Fair Value of $21.22 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, that upside story can unravel if competition squeezes lending yields, or if a weak IPO and M&A market limits exits for portfolio companies.

Find out about the key risks to this Hercules Capital narrative.

Build Your Own Hercules Capital Narrative

If you see the numbers differently or prefer to stress test your own assumptions, it is quick to build a fresh Hercules view yourself: Do it your way.

A great starting point for your Hercules Capital research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.

Ready for more investment ideas?

If Hercules has you thinking differently about risk and reward, do not stop here. Widen your scope and let a few more ideas challenge your watchlist.

Spot potential bargains early by scanning these 880 undervalued stocks based on cash flows to look for companies priced below their cash flow outlooks. Explore changes in technology by checking out these 24 AI penny stocks built around businesses tied to artificial intelligence themes. Add income candidates to your shortlist by reviewing these 13 dividend stocks with yields > 3% that focus on higher yielding dividend payers.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include HTGC.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments